AI Article Synopsis

  • Caveolins are crucial proteins found in caveolae, which are small indentations in cell membranes that are involved in various cellular functions like transporting substances and signaling.
  • A new mutation in the caveolin-3 gene (CAV3) was discovered in two brothers, leading to symptoms like high creatine kinase levels, muscle pain, and high cholesterol.
  • The brothers' muscle biopsies showed decreased caveolin-3, supporting the harmful impact of the mutation and suggesting a connection between CAV3 mutations and high cholesterol levels.

Article Abstract

Caveolins are essential proteins in caveolae architecture, small plasma membrane invaginations that play a key role in a variety of cellular processes, including vesicular trafficking and signal transduction. Mutations in the gene encoding caveolin-3 (CAV3) cause a broad spectrum of clinical phenotypes, ranging from isolated hyperCKemia to most severe limb girdle muscular dystrophy and cardiomyopathy. We report a novel heterozygous p.Val44Met (c.130G > A) CAV3 mutation in two brothers presenting with persistent elevation of serum creatine kinase, myalgia and hypercholesterolemia. Immunofluorescence study with anticaveolin-3 antibodies on muscle biopsy of the proband confirmed a reduced immuno-reactivity of caveolin-3 on the sarcolemma. This findings support the pathogenic effect of this novel mutation and extend the genotypic and clinical spectrum of Caveolinopathies. Finally, we discuss the hypothesis that the association between CAV3 mutations and hypercholesterolemia may not be coincidental.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2020.105687DOI Listing

Publication Analysis

Top Keywords

myalgia hypercholesterolemia
8
novel missense
4
missense mutation
4
cav3
4
mutation cav3
4
cav3 gene
4
gene italian
4
italian family
4
family persistent
4
persistent hyperckemia
4

Similar Publications

Dyslipidemia, a significant risk factor for cardiovascular disease (CVD), is marked by abnormal lipid levels, such as the elevated lowering of low-density lipoprotein cholesterol (LDL-C). Statins are the first-line treatment for LDL-C reduction. Pitavastatin (PIT) has shown potential in lowering LDL-C and improving high-density lipoprotein cholesterol (HDL-C).

View Article and Find Full Text PDF

Lipid-lowering therapy (LLT) includes a diverse group of pharmaceuticals designed to reduce blood levels of cholesterol and triglyceride (TG), helping to prevent cardiovascular diseases like myocardial infarction and stroke. LLT includes treatment with several lipid-lowering drugs (LLD), including hydroxymethylglutaryl (HMG-CoA) reductase inhibitors (statin), PCSK9 Inhibitors, cholesterol-absorbing inhibitors (Ezetimibe), Bile Acid Sequestrants, Fibrates, Niacin (Vitamin B3), Omega-3 Fatty Acids, Bempedoic Acid, and combination therapy. The efficacy and safety of these molecules vary widely.

View Article and Find Full Text PDF

Introduction: Evolocumab's short-term efficacy and safety were proven in phase-3 clinical trial, but its long-term safety and effectiveness in the Saudi population are yet to be studied. The aim of this study was to assess the long-term safety and effectiveness of evolocumab in Saudi patients with primary hypercholesterolemia or mixed dyslipidemia.

Method: A retrospective cohort study evaluated adult patients who had newly been prescribed evolocumab for hypercholesterolemia or mixed dyslipidemia.

View Article and Find Full Text PDF
Article Synopsis
  • Lupus nephritis (LN) is a kidney inflammation linked to systemic lupus erythematosus (SLE), and the study investigated the clinical and laboratory differences between LN and non-LN SLE patients at a university hospital in Kraków, Poland.
  • Out of 921 SLE patients analyzed, 331 had LN, which presented at a younger age (29 vs. 37 years) and a higher male proportion compared to non-LN patients, who also had a higher occurrence of certain antibodies like anti-cardiolipin IgM.
  • LN patients showed more severe symptoms, required more immunosuppressive treatment, and had specific risk factors for experiencing multiple LN flares, underscoring the need for
View Article and Find Full Text PDF

Review of Recent Literature and Updates in Nonstatin Cholesterol Management.

Mayo Clin Proc

September 2024

Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston TX; Denver Harbor Family Health Center, Vecino Health Centers, Houston, TX.

The guidelines for cholesterol management have been updated over the years from treat-to-target using any drug class to emphasis on statins without treatment targets to a hybrid of the 2 approaches. The most recent guideline updates include newer nonstatin lipid-lowering therapies (LLTs), low-density lipoprotein cholesterol (LDL-C) reduction goals, and LDL-C thresholds considering secondary prevention and cardiovascular risk. Although statins have been the mainstay of LLT for years, newer pharmacological agents such as proprotein convertase subtilisin-kexin type 9 inhibitor(s) (PCSK9i) monoclonal antibodies, small interfering RNA PCSK9i, and bempedoic acid to optimize LDL-C levels may be underutilized in clinical practice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!